ES2093427T3 - Corte dirigido de arn utilizando ribonucleasa p eucariotica y secuencia guia externa. - Google Patents

Corte dirigido de arn utilizando ribonucleasa p eucariotica y secuencia guia externa.

Info

Publication number
ES2093427T3
ES2093427T3 ES93910848T ES93910848T ES2093427T3 ES 2093427 T3 ES2093427 T3 ES 2093427T3 ES 93910848 T ES93910848 T ES 93910848T ES 93910848 T ES93910848 T ES 93910848T ES 2093427 T3 ES2093427 T3 ES 2093427T3
Authority
ES
Spain
Prior art keywords
egs
rna
rnaase
loop
cleavage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93910848T
Other languages
English (en)
Inventor
Yan Yuan
Cecilia L Guerrier-Takada
Sidney Altman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES2093427T3 publication Critical patent/ES2093427T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

HA SIDO DESCUBIERTO QUE CUALQUIER RNA PUEDE SER TERMINADO POR DESDOBLAMIENTO DE RNAASA P A PARTIR DE CELULAS EUCARIOTICAS, POR EJEMPLO, CELULAS HELA HUMANAS, USANDO UN OLIGORIBONUCLEOTIDO ADECUADAMENTE DISEÑADO ("SECUENCIA DE GUIA EXTERNA, O EGS) PARA FORMAR UN HIBRIDO CON EL RNA DE DESTINO, POR LO QUE SE CREA UN SUSTRATO PARA DESDOBLAMIENTO POR RNAASA P IN VITRO. HAY DOS CLASES DE EGS QUE PUEDEN TERMINAR RNA POR DESDOBLAMIENTO POR RNAASA HUMANO. ESTAS SE PREPARAN POR TRANSCRIPCION DE UN PEQUEÑO FRAGMENTO DE DNA QUE CONTIENE UNA SECUENCIA QUE CODIFICA UN RNA QUE PUEDE ASUMIR UNA ESTRUCTURA SECUNDARIA TIPO TRNA. EN LAS PRIMERAS CLASES, LA ESTRUCTURA CARECE AL MENOS DE LOS PRIMEROS TRECE NUCLEOTIDOS DESDE EL TERMINO 5'' DE LA SECUENCIA TIPO TRNA, LOS TALLOS Y LAZOS ANTICODON, EL BUCLE VARIABLE O PARTE DEL BUCLE VARIABLE. LA EGS MAS EFICIENTE CON RNAASA P HUMANA ES EL EGS EN EL QUE EL TALLO Y BUCLE ANTICODON HAN SIDO BORRADOS. EN LA SEGUNDA CLASE, EL EGS TIENE CAMBIOS EN AMBOS EL EQUIVALENTE DEL BUCLE T Y EL TALLO ANTICODON DEL SEGMENTO TIPO TRNA DEL EGS. TAMBIEN SE DESCRIBEN METODOS PARA SELECCIONAR ALEATORIAMENTE Y PARA EXPRESAR UN EGS ADECUADO, EN VIVO, PARA HACER UNA OBTENCION DE RNA SELECCIONADO POR DESDOBLAMIENTO DE LA CELULA ANFITRION RNAASA P, EVITANDO ASI LA EXPRESION DE LA FUNCION DEL RNA DE OBJETIVO. LOS METODOS Y COMPOSICIONES DEBEN SER USADOS PARA PREVENIR LA EXPRESION DE GENES QUE CAUSEN ENFERMEDAD EN VIVO.
ES93910848T 1992-04-28 1993-04-28 Corte dirigido de arn utilizando ribonucleasa p eucariotica y secuencia guia externa. Expired - Lifetime ES2093427T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87509992A 1992-04-28 1992-04-28
US93193792A 1992-08-18 1992-08-18

Publications (1)

Publication Number Publication Date
ES2093427T3 true ES2093427T3 (es) 1996-12-16

Family

ID=27128368

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93910848T Expired - Lifetime ES2093427T3 (es) 1992-04-28 1993-04-28 Corte dirigido de arn utilizando ribonucleasa p eucariotica y secuencia guia externa.

Country Status (10)

Country Link
EP (1) EP0638121B1 (es)
JP (1) JP3015463B2 (es)
AT (1) ATE140482T1 (es)
AU (1) AU669367B2 (es)
CA (1) CA2117903C (es)
DE (1) DE69303712T2 (es)
DK (1) DK0638121T3 (es)
ES (1) ES2093427T3 (es)
GR (1) GR3020859T3 (es)
WO (1) WO1993022434A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
WO1999027135A2 (en) * 1997-11-21 1999-06-03 Yale University Method for identifying and inhibiting functional nucleic acid molecules in cells
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
AU9684601A (en) 2000-10-12 2002-04-22 Univ Rochester Compositions that inhibit proliferation of cancer cells
US7811992B2 (en) 2002-02-06 2010-10-12 Stasys Technologies, Inc. Anti-infarction molecules
EP2116604A1 (en) 2002-08-05 2009-11-11 University of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
ATE512223T1 (de) 2004-04-29 2011-06-15 Univ Yale Nukleaseresistente externe führungssequenzen zur behandlung von entzündlichen und virusbedingten atemwegserkrankungen
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP2395076A1 (en) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
AU2007223427A1 (en) 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
EP3034083B1 (en) 2006-09-21 2020-12-09 University of Rochester Antisense oligonucleotides for use in treating myotonic dystrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2009114614A2 (en) 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2009137686A1 (en) 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2010074924A1 (en) 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
WO2010151638A1 (en) 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110274745A1 (en) 2009-11-10 2011-11-10 Lipella Pharmaceuticals Inc. Instillation of liposomal formulation of sirna and antisense oligonucleotides
US8889615B2 (en) 2009-12-31 2014-11-18 New York University Methods for promoting epithelialization and healing of chronic wounds
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
CN103608680A (zh) 2010-12-14 2014-02-26 詹姆士·W·里拉尔德 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US9801948B2 (en) 2011-09-21 2017-10-31 Yale University Antimicrobial compositions and methods of use thereof
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
BR112017008696A2 (pt) 2014-10-27 2017-12-26 Univ Central Florida Res Found Inc métodos e composições para células exterminadoras naturais
AU2017306422A1 (en) 2016-08-03 2019-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
EP4060035A4 (en) * 2021-01-27 2023-01-25 CJ CheilJedang Corporation NEW VARIANT OF RIBONUCLEASE P, AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING THE SAME

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2750127B2 (ja) * 1988-07-29 1998-05-13 三共株式会社 リボザイムによるポリリボヌクレオチド特定部位の切断方法
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P

Also Published As

Publication number Publication date
EP0638121A1 (en) 1995-02-15
CA2117903C (en) 1999-01-12
EP0638121B1 (en) 1996-07-17
JPH07507683A (ja) 1995-08-31
DE69303712T2 (de) 1997-02-20
CA2117903A1 (en) 1993-11-11
ATE140482T1 (de) 1996-08-15
DK0638121T3 (da) 1996-08-12
JP3015463B2 (ja) 2000-03-06
WO1993022434A2 (en) 1993-11-11
DE69303712D1 (de) 1996-08-22
AU4119893A (en) 1993-11-29
WO1993022434A3 (en) 1993-12-23
GR3020859T3 (en) 1996-11-30
AU669367B2 (en) 1996-06-06

Similar Documents

Publication Publication Date Title
GR3020859T3 (en) Targeted cleavage of rna using eukaryotic ribonuclease p and external guide sequence.
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
MX9606476A (es) Inhibicion citoplasmica de expresion de genes.
ES2109924T3 (es) Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
ATE331034T1 (de) Samenstrenung resistenz
KR970701199A (ko) 성장 정지 호메오박스 유전자(Growth Arrest Homeobox Gene)
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
KR970707162A (ko) II종 포스포리파제 A2 저해작용을 갖는 신규한 모노클로날 항체 및 그 일부를 포함하는 단백질(Novel monoclonal antibody having inhibitory effect on type II phospholipase A2 and protein containing a part of the same)
KR930019822A (ko) 가광견병 바이러스 폴리뉴클레오티드 및 바이러스-내성 진핵세포의 제조를 위한 그의 용도
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
BR9712532A (pt) Método para aumentar o nìvel de expressão de um transgene população de células monocotiledÈneas,plantas e sementes
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena
Rogers et al. Unstable high molecular weight inverted repetitive DNA in human lymphocytes
Arnn ULTRASTRUCTURAL AND IMMUNOFLUORESCENT INVESTIGATIONS OF SPOT DESMOSOMES.
JPS6480281A (en) Plant cell and body
FEDOROV The structure of DNA and the transformation of cells
Shall Stimulation of ADP-ribosylation of nuclear proteins in permeabilized cells after treatment of mouse lymphoma (L1210) cells with the alkylating agent, dimethyl sulphate
Marsh et al. Role of microspikes in the aggregation of fixed and live haemocytes
ATE85359T1 (de) Gentamicin-resistenzgene und ihre verwendung als marker.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 638121

Country of ref document: ES